{"title":"A new zebrafish epilepsy model","authors":"Jorge Ferreira","doi":"10.1038/s41684-025-01594-5","DOIUrl":null,"url":null,"abstract":"<p>Epilepsy affects approximately 70 million people globally, with 30–40% of patients experiencing drug-resistant seizures despite treatment with multiple antiseizure medications (ASMs). To address this issue, in a study in <i>Disease Models & Mechanisms</i>, the team developed a novel zebrafish model targeting <i>slc25a22a</i>, the ortholog of human <i>SLC25A22</i>—a gene associated with a range of epileptic conditions. Unlike existing zebrafish models, which often rely on gene knockdowns and show weak seizure phenotypes, the new CRISPR-Cas9–generated <i>slc25a22a</i> knockout exhibits robust epilepsy traits, including spontaneous seizures, behavioral hyperactivity and electrophysiological hyperexcitability. Importantly, treatment with valproic acid effectively suppressed these phenotypes, highlighting the model’s relevance for both mechanistic studies and drug screening. These findings indicate that <i>slc25a22a</i> can be a promising therapeutic target for refractory epilepsy and establish this zebrafish line as a valuable platform for preclinical research into novel ASMs.</p><p><b>Original reference:</b> Lee, S.-H. et al. <i>Dis. Model & Mech</i>. <b>18</b>, dmm052275 (2025)</p>","PeriodicalId":17936,"journal":{"name":"Lab Animal","volume":"13 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lab Animal","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1038/s41684-025-01594-5","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Epilepsy affects approximately 70 million people globally, with 30–40% of patients experiencing drug-resistant seizures despite treatment with multiple antiseizure medications (ASMs). To address this issue, in a study in Disease Models & Mechanisms, the team developed a novel zebrafish model targeting slc25a22a, the ortholog of human SLC25A22—a gene associated with a range of epileptic conditions. Unlike existing zebrafish models, which often rely on gene knockdowns and show weak seizure phenotypes, the new CRISPR-Cas9–generated slc25a22a knockout exhibits robust epilepsy traits, including spontaneous seizures, behavioral hyperactivity and electrophysiological hyperexcitability. Importantly, treatment with valproic acid effectively suppressed these phenotypes, highlighting the model’s relevance for both mechanistic studies and drug screening. These findings indicate that slc25a22a can be a promising therapeutic target for refractory epilepsy and establish this zebrafish line as a valuable platform for preclinical research into novel ASMs.
Original reference: Lee, S.-H. et al. Dis. Model & Mech. 18, dmm052275 (2025)
期刊介绍：
LabAnimal is a Nature Research journal dedicated to in vivo science and technology that improves our basic understanding and use of model organisms of human health and disease. In addition to basic research, methods and technologies, LabAnimal also covers important news, business and regulatory matters that impact the development and application of model organisms for preclinical research.
LabAnimal's focus is on innovative in vivo methods, research and technology covering a wide range of model organisms. Our broad scope ensures that the work we publish reaches the widest possible audience. LabAnimal provides a rigorous and fair peer review of manuscripts, high standards for copyediting and production, and efficient publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
